507 related articles for article (PubMed ID: 18344152)
1. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
2. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol.
Nessler J; Nessler B; Golebiowska-Wiatrak R; Palka I; Gackowski A; Kitlinski M; Melander O; Fedorowski A
Cardiol J; 2013; 20(2):144-51. PubMed ID: 23558872
[TBL] [Abstract][Full Text] [Related]
3. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
[TBL] [Abstract][Full Text] [Related]
4. Limited predictive value of cardiopulmonary exercise indices in patients with moderate chronic heart failure treated with carvedilol.
Corrà U; Mezzani A; Bosimini E; Scapellato F; Temporelli PL; Eleuteri E; Giannuzzi P
Am Heart J; 2004 Mar; 147(3):553-60. PubMed ID: 14999209
[TBL] [Abstract][Full Text] [Related]
5. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
[TBL] [Abstract][Full Text] [Related]
6. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure.
Kinugawa T; Kato M; Ogino K; Osaki S; Igawa O; Hisatome I; Shigemasa C
J Card Fail; 2003 Aug; 9(4):318-24. PubMed ID: 13680553
[TBL] [Abstract][Full Text] [Related]
7. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
8. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
[TBL] [Abstract][Full Text] [Related]
9. Restrictive left ventricular filling pattern and its effect on the clinical course of systolic heart failure in patients receiving carvedilol.
Nessler J; Nessler B; Kitliński M; Stepniewski M; Piwowarska W
Cardiol J; 2008; 15(4):329-37. PubMed ID: 18698541
[TBL] [Abstract][Full Text] [Related]
10. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
12. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
Tatli E; Kurum T
Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
[TBL] [Abstract][Full Text] [Related]
13. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
14. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
[TBL] [Abstract][Full Text] [Related]
15. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
[TBL] [Abstract][Full Text] [Related]
17. Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients.
Boffa GM; Zaninotto M; Bacchiega E; Nalli C; Forni M; Tiso E; Cacciavillani L; Razzolini R; Plebani M
Ital Heart J; 2005 Feb; 6(2):125-32. PubMed ID: 15819505
[TBL] [Abstract][Full Text] [Related]
18. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
19. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
Tatli E; Kurum T; Aktoz M; Buyuklu M
Int J Cardiol; 2008 Apr; 125(2):273-6. PubMed ID: 18053592
[TBL] [Abstract][Full Text] [Related]
20. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
